Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Colorcon
Johnson and Johnson
Medtronic
Mallinckrodt

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,242,131

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,242,131 protect, and when does it expire?

Patent 8,242,131 protects INTERMEZZO and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 8,242,131
Title:Methods of treating middle-of-the-night insomnia
Abstract: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.
Inventor(s): Singh; Nikhilesh (Mill Valley, CA), Pather; Sathasivan Indiran (Greenbrae, CA)
Assignee: Transcept Pharmaceuticals, Inc. (Pt. Richmond, CA)
Application Number:11/439,874
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,242,131
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 8,242,131

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Purdue Pharma INTERMEZZO zolpidem tartrate TABLET;SUBLINGUAL 022328-001 Nov 23, 2011 DISCN Yes No   Start Trial   Start Trial METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA   Start Trial
Purdue Pharma INTERMEZZO zolpidem tartrate TABLET;SUBLINGUAL 022328-002 Nov 23, 2011 DISCN Yes No   Start Trial   Start Trial METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,242,131

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006249761   Start Trial
Brazil PI0609984   Start Trial
Canada 2609330   Start Trial
China 101198327   Start Trial
European Patent Office 1883408   Start Trial
Hong Kong 1118203   Start Trial
Israel 187309   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Colorcon
Moodys
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.